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Abstract
The use of nondepleting Ab specific for CD4 and CD8 is an effective strategy to tolerize CD4+ 
and CD8+ T cells in a tissue-specific manner. We reported that coreceptor therapy reverses 
diabetes in new onset NOD mice. A striking feature of coreceptor-induced remission is the 
purging of T cells from the pancreatic lymph nodes (PLN) and islets of NOD mice. Evidence 
indicates that Ab binding to the coreceptors promotes T cell egress from these tissues. The current 
study examined how coreceptor therapy affects the migration of CD4+ T cells residing in the PLN 
of NOD mice. αCD4 Ab treatment resulted in an increased frequency of PLN but not splenic 
CD4+ T cells that exhibited a polarized morphology consistent with a migratory phenotype. 
Furthermore, PLN CD4+ T cells isolated from αCD4 versus control Ab-treated animals displayed 
increased in vitro chemotaxis to chemoattractants such as sphingosine-1-phosphate and CXCL12. 
Notably, the latter was dependent on activation of the small Rho GTPases Rac1 and Rac2. Rac1 
and Rac2 activation was increased in Ab-bound CD4+ T cells from the PLN but not the spleen, 
and knockdown of Rac expression blocked the heightened reactivity of Ab-bound PLN CD4+ T 
cells to CXCL12. Interestingly, Rac1 and Rac2 activation was independent of Rac guanine 
nucleotide exchange factors known to regulate T cell activity. Therefore, Ab binding to CD4 
initiates a novel pathway that involves inflammation-dependent activation of Rac, and 
establishment of altered T cell migratory properties.
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INTRODUCTION
Type 1 diabetes (T1D) is a T cell-mediated autoimmune disease in which the insulin-
secreting β cells of the islets of Langerhans are destroyed. Diabetogenic CD4+ and CD8+ T 
cells are stimulated by β cell-antigen laden APC in the draining pancreatic lymph nodes 
(PLN), and then traffick to the islets to mediate inflammation and ultimately β cell 
destruction (1-4). To date, most immunotherapies have focused on targeting T cells as a 
means to prevent and/or treat T1D (5-11). We and others have applied Ab specific for CD4 
and CD8 to manipulate coreceptor molecule signaling and the activity of pathogenic CD4+ 
and CD8+ T cells, as well as Foxp3-expressing regulatory CD4+ T cells (12-17). Binding of 
CD4 and CD8 to MHC-peptide complexes results in activation of the Src kinase p56lck 
(Lck) and downstream signaling events that directly impact TCR signaling, as well as 
modulate T cell activation either positively or negatively in a TCR-independent manner (18). 
Ab blockade of CD4 or CD8 for instance, induces a hyporesponsive phenotype by 
increasing the threshold for T cell activation (19, 20). Recently, we reported that a short 
course of nondepleting αCD4 and αCD8 Ab induces rapid remission in new onset diabetic 
NOD mice (14). Once established, remission is indefinite and normal immunity unperturbed 
in treated NOD mice. Strikingly, induction of remission by coreceptor therapy is marked by 
a significant decrease in T cell cellularity in both the PLN and islets, but not in noninflamed 
tissue such as the spleen. This “purging” is independent of apoptosis induction, suggesting a 
novel scenario in which the trafficking properties of PLN and islet resident T cells are 
altered by Ab binding to CD4 and CD8. The latter is consistent with earlier findings 
demonstrating that binding of HIV gp120 to CD4 affects human T cell chemotaxis in vitro 
(21). Furthermore IL-16, a CD4 binding ligand, promotes trafficking of β cell-specific type 
1 effectors to the pancreas of NOD mice (22).
T cells in general are highly migratory (23), continually cycling between lymphatics and 
blood (24), and entering sites of inflammation (25, 26). Migration is an active process 
requiring polarization of T cells and interactions that include chemokines and adhesion 
molecules (27-31). T cell polarization is characterized by rearrangement of the actin 
cytoskeleton to form a leading edge in the direction of migration, with a retracting tail at the 
posterior of the cell (32). The small Rho GTPases Rac1, Rac2, RhoA and Cdc42 play a key 
role in regulating actin cytoskeleton reorganization induced by TCR and/or chemokine 
receptor (CKR) signaling (33, 34). Rho GTPases are tightly controlled and the transition 
from an inactive GDP-bound to an active GTP-bound state is regulated by various guanine 
nucleotide exchange factors (GEF) (35, 36).
Rac regulates T cell migration by inducing a branch actin network termed the lamellipodia at 
the leading edge, which becomes clustered with CKR such as CCR2, CCR5, and CXCR4 
(37, 38). Clustering of adhesion molecules to the poles, such as LFA-1, which slow 
circulating T cells and facilitate transendothelial migration from blood to lymphatics and 
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vice versa, as well as promote T cell scanning of APC (32, 39, 40). Rac activation influences 
various aspects of T cell migration including entry and egress of lymphoid tissues, and entry 
into target tissues (31). The different outcomes of Rac activation in T cells is contextual, and 
partly attributed to the identity of the activating RacGEF, which include the Vav, Tiam, and 
Dock families (33, 41-45). Dock2 promotes T cell homing to lymph nodes (46), whereas 
Tiam1-mediated Rac activation is associated with T cell adhesion and transendothelial 
migration (43). Furthermore, the recruitment of a given RacGEF and induction of 
downstream effectors of Rac are dependent on the nature of the stimulus. For instance 
distinct RacGEF and Rac effectors are activated by TCR and particular CKR (34, 47).
In the current study, the effects of αCD4 Ab binding on the migratory properties of T cells 
in the PLN of NOD mice were investigated. We show for the first time that αCD4 Ab alters 
CD4+ T cell migration due to inflammation-dependent activation of Rac. These findings 
establish a novel pathway by which CD4 regulates T cell function and migration, which is 
independent and distinct from the classical TCR signaling cascade.
MATERIALS AND METHODS
Mice and treatments
NOD/LtJ and NOD.Cg-Tg(TcraBDC2.5)1Doi Tg(TcrbBDC2.5)2Doi/DoiJ (NOD.BDC) 
mice were bred and maintained in specific pathogen-free facilities at the University of North 
Carolina at Chapel Hill (UNC-CH). All animal experiments were approved by the UNC-CH 
Institutional Animal Care and Use Committee.
12 wk-old nondiabetic NOD female mice were used for all experiments. Animals received a 
single i.p. injection of 600 μg of the αCD4 clone YTS177.9 or 2A3, a rat IgG2a isotype 
control (BioXCell). In some experiments NOD mice were injected i.p. with 75 mg/kg of 
Ly294002 (LC Laboratories) 6 h prior to Ab treatment, and then daily for 3 d. Alternatively, 
NOD mice received 3 mg/kg of NSC237666 (Santa Cruz Biotechnology) i.p. 2 h prior to Ab 
treatment, and then every 12 h for 3 d. For calcineurin inhibition, NOD mice were injected 
i.p. with 1 mg/kg of FK506 (Abcam) 6 h prior to Ab treatment, and then daily for 5 d.
Primary cell isolation
Spleen and PLN suspensions were prepared by mechanical dissociation, RBC lysed with 
ACK buffer, and single cells filtered through a 40 μM nylon cell strainer (Corning). 
Peripheral blood lymphocytes were isolated from 25 μl of blood using Lympholyte M 
(Cedarlane) per manufacturers’ instructions. CD4+ T cell enrichment was performed on an 
Automacs Separator using a CD4 T cell isolation kit according to the manufacturer’s 
specifications (Miltenyi).
Ab
Ab used for FACS and confocal microscopy were purchased from eBiosciences, Abcam, 
Cell Signaling, Santa Cruz Biotechnology and R&D Systems. Ab specific for CD3 
(145-2C11), LFA-1 (M17/4), CD4 (RM4-4), CD8 (53-6.7), CD62L (MEL-14), CXCR4 
(L276F12; rat IgG2b), S1PR1 (713412; rat IgG2a), rat IgG2a (RTK2758), and rat IgG2b 
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(RTK4530) were used for FACS. Ab specific for Rac1 (O.T.127), Rac2 (goat polyclonal), 
Lck (rabbit polyclonal), Lck pTyr505 (rabbit polyclonal), Lck pTyr394 (rabbit polyclonal), 
and AKT pSer473 (rabbit polyclonal) were employed for immunoblotting.
The YTS177.9 hybridoma was a gift from Dr. Waldmann (Oxford, UK); YTS177 Ab was 
purified via ammonium sulfate precipitation from culture supernatants.
Flow cytometry and microscopy
For flow cytometry, single cell suspensions were stained on ice with Ab in PBS+2% FBS 
with 1 mM EDTA. Dead cells were excluded by Live/Dead Fixable Yellow stain (Life 
Technologies). Where appropriate, cells were fixed with 1.5% paraformaldehyde in PBS
+2% FBS. Flow cytometric data was acquired at the UNC-CH Flow Cytometry Facility 
using a Cyan cytometer (DakoCytomation), and analyzed with Summit (DakoCytomation) 
or FlowJo (Tree Star Inc) software.
For microscopy, tissues were homogenized directly in 1.5% paraformaldehyde in PBS+2% 
FBS, and stained with anti-CD3 (145-2C11), anti-LFA-1 (M17/4), and Alexa 488-
conjugated phalloidin (Life Technologies). Confocal microscopy data was acquired at the 
UNC-CH Microscopy Services Laboratory using the Olympus FV500 Confocal Laser 
Scanning microscope. Image analysis was completed using either Image J software (NIH).
Adoptive transfer and measurement of T cell entry into lymphoid tissues
Donor NOD.BDC mice were injected i.p with 600 μg of YTS177 or 2A3 or 100 μg of 
αCD11α (M17/4; BioXCell) and αCD49d (Clone PS2; BioXCell), and 12 h later BDC 
CD4+ T cells purified from the spleen via magnetic beads (Miltenyibiotech). BDC CD4+ T 
cells from 2A3 (0.5 μM) or YTS177 and αCD11α/αCD49d (5.0 μM) were differentially 
labeled with CellTrace Violet (CTV; Sigma), and co-transferred (YTS177/2A3; αCD11α
+αCD49d/2A3; 2A3/2A3) at a 1:1 ratio into 10 wk-old NOD female mice. 12 hr post-
transfer, labeled T cells were identified via flow cytometry in the PLN and spleen of NOD 
recipients.
In vitro migration assay
Cell migration assays were performed in transwell plates (Corning) of 6.5-mm diameter with 
5-μm pore filters. The upper transwell plate was either left uncoated or coated with 10 μg/ml 
collagen IV, or a primary mouse endothelial cell (EC) monolayer. Pulmonary EC were 
isolated from 1 wk-old NOD mice as described (48), and grown in EGM-2 Bullet Kit 
(Lonza). T cells (5×105) suspended in Aim V medium (Life Technologies) were rested for 1 
h and then cultured in the upper chamber. Migration to the lower chamber in response to 
murine sphingosine-1-phosphate (S1P; Sigma) or CXCL12 (Sigma) at 37°C and 5% CO2 
was measured after 4 h by flow cytometry, and enumerated using AccuCheck counting 
beads (Life Technologies).
Preparation of GST-PBD and GST-RhoAG17A and pulldown assay
pGEX GST-PBD and pGEX GST-RhoAG17A fusion proteins were prepared from lysates 
from Bl21 E. coli cells induced with 100 μM IPTG for 16 h at 24°C. For GST-PBD, 
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bacterial cells were lysed in 20 mM Tris pH 7.8, 1% Triton X-100, 10 mM MgCl2 1 mM 
DTT, 1mM PMSF, and 10 μg/ml aprotinin and leupeptin. For GST-RhoAG17A, bacterial 
cells were lysed in 20 mM HEPES pH 7.8, 150 mM NaCl, 10 mM MgCl2, 1mM PMSF, and 
10 μg/ml aprotinin and leupeptin. Recombinant proteins were isolated with glutathione-
Sepharose 4B beads (GE Healthcare) at 4°C for 4 h. The beads were sedimented and washed 
3 times in 20 mM HEPES, pH 7.5, 150 mM NaCl, and 1 mM DTT.
Rac activation assays were performed as described (49). Briefly, T cells were lysed in 300 
μL of 10 mM MgCl2, 500 mM NaCl, 50 mM Tris, pH 7.8, 1% Triton X-100, 0.1% SDS, 
0.5% deoxycholate, 1mM PMSF, and 10 μg/ml aprotinin and leupeptin. Lysates were cleared 
at 14,000g at 4°C for 3 min and incubated with ≥ 20 μg of GST-PBD for 20 min at 4°C. 
Beads were then washed 3 times in 50 mM Tris, pH 7.4, 10 mM MgCl2, 150 mM NaCl, 1% 
Triton X-100, 1mM PMSF, and 10 μg/ml aprotinin and leupeptin. Active GEF were assayed 
by binding to GST-RhoAG17A as described (50) with the following changes. T cells were 
lysed in 150 mM NaCl, 20 mM HEPES, pH 7.6, 10 mM MgCl2, 1% Triton X-100 1mM 
PMSF, and 10 μg/ml aprotinin and leupeptin, and incubated with GST-RhoAG17A beads for 
1 h at 4°C, and washed in the same lysis buffer. Samples were then analyzed by Western 
blot.
Enrichment of phospho-tyrosine containing proteins
Cells were lysed in preheated gel sample buffer containing 200 mM Tris pH 6.8, 20% 
glycerol, 4% SDS and 5% 2-ME, and boiled for 5 min and DNA sheared. Samples were then 
diluted with 20 volumes of 20 mM Tris, pH 7.5, 150 mM NaCl, 1% Triton X-100 and 1% 
deoxycholate, 10 μg/ml othrovanidate, 1mM PMSF, and 10 μg/ml aprotinin and leupeptin, 2 
μg of αphospho-tyrosine Ab (PY-20) for 2 h at 4°C. Protein G-Sepharose was then added 
and samples rotated for 2 h at 4°C. Beads were washed in dilution buffer and analyzed by 
Western blot.
Western blotting
Samples were run on SDS-PAGE gels and transferred to polyvinylidene fluoride membranes 
(Millipore). Membranes were blocked and incubated with primary Ab followed by goat 
αmouse or goat αrat secondary Ab conjugated with horseradish peroxidase. Blots were 
developed with a chemiluminescent HRP substrate, and visualized on x-ray film or 
ChemiDoc™ MP System (BioRad) and corresponding software. For quantification, blots 
were scanned and the intensity values determined using Image J software (NIH) and protein 
levels normalized to control protein levels.
Quantitative real-time PCR
PLN CD4+ T cells were isolated via MACS CD4 negative selection (Miltyni), RNA 
prepared using the QIAshredder and RNeasy PLUS columns (Qiagen), and cDNA 
synthesized using SuperScript III (Life Technologies) according to manufacturers’ 
recommendations. cDNA was amplified via a Maxima SYBR green master mix (Thermo-
Fisher) and an ABI Prism 7500 (Applied Biosystems). Ct values were calculated by the 
ΔΔCt method and ABI Sequence Detection System software.
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Lentivirus vector knockdown of Rac1 and Rac2
Lentivirus vectors were produced by the UNC-CH Lenti-shRNA Core Facility using 
methods described (51). Vectors were constructed with shRNA sequences identified in the 
UNC shRNA library specific for 5 regions of Rac1 (NM_009007), Rac2 (NM_00908), or β-
globulin (control). For lentivirus vector transduction, PLN-derived T cells were cultured in 
either Aim V or RPMI plus 10% FBS and stimulated with 1 μg/ml αCD3 (145-2C11), 2 
μg/ml αCD28 (37.51), and 100 U/ml IL-2 (Peprotech) for 24 h. Lentivirus vector particles 
(>5×104 IU) were added to the cultures for 24 h, after which T cells were washed, and 
cultured for 72 h with 5 μg/ml puromycin. Transduction efficiency was determined to be 
>75%. Live cells were isolated via gradient centrifugation utilizing Lympholyte M.
Statistics
Data represent mean ± SEM. Statistical comparisons of differences between sample means 
used the two-tailed Student’s t test and was calculated using Prism (Version 6.0; GraphPad).
RESULTS
αCD4 induced purging of PLN is associated with increased T cell polarization
Reversal of diabetes in NOD mice by αCD4 (YTS177) and αCD8 (YTS105) Ab is marked 
by purging of CD4+ and CD8+ T cells from the PLN and pancreas 6 d post-treatment, which 
is independent of apoptosis induction (14). To define the short-term effects of coreceptor 
therapy on CD4+ T cells, 12 wk-old pre-diabetic NOD mice were treated with YTS177 or 
the isotype control 2A3, and T cells assessed via flow cytometry. At 24 h post-YTS177 
treatment PLN and splenic CD4+ T cells exhibited an ~4-fold reduction in surface CD4 
expression (Fig. 1A, Supplementary Fig. 1). Surface levels of CD62L and LFA-1 (CD11α) 
were also significantly reduced by YTS177 binding (Fig. 1A, Supplementary Fig. 1). 
Furthermore, YTS177 induced up to a 2-fold reduction in PLN CD4+ T cell numbers over 
24 h (Fig. 1B). In contrast, the number of splenic CD4+ T cells was increased in YTS177 
versus 2A3-teated animals within this time period (Fig. 1B). In addition, YTS177 induced a 
25% increase in T cells in peripheral blood 72 h post-Ab treatment (Fig. 1C).
YTS177-mediated T cell purging may be due to blockade of TCR signaling, which 
influences T cell trafficking properties. Indeed, YTS177 binding of CD4 in vivo resulted in 
increased phosphorylation of pTyr505, the inhibitory isoform of Lck (Supplementary Fig. 
2A). Accordingly, NOD mice were treated with the calcineurin inhibitor FK506. Blocking 
downstream TCR signaling alone did not decrease PLN CD4+ T cell numbers, nor was 
YTS177-induced purging of PLN CD4+ T cells altered, although an increase in splenic 
CD4+ T cells was observed (Fig. 1D). Therefore, blockade of TCR signaling is insufficient 
to promote and/or prevent PLN T cell purging, suggesting that additional events induced by 
YTS177 binding are necessary.
In support of the latter, morphological analysis via confocal microscopy after YTS177 
treatment showed an ~2-fold increase in polarized T cells in the PLN but not the spleen (Fig. 
1E). These T cells displayed an oblong morphology with F-actin and LFA-1 localized to the 
cellular poles, typical of a T cell migratory phenotype (Fig. 1F). Together these results 
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demonstrate that PLN T cell purging is induced shortly after Ab binding to CD4, which is 
independent of TCR signaling and reflected by a phenotype consistent with T cell migration.
Ab binding of CD4 has no effect on PLN entry by CD4+ T cells
One possible explanation for the decreased PLN CD4+ T cells is that YTS177 binding 
blocked trafficking of CD4+ T cells into the PLN, while tissue egress was unaffected. For 
instance LFA-1 (CD11α) and CD62L expression, which was reduced on CD4+ T cells by 
YTS177 binding (Fig. 1A) are required for efficient T cell entry into lymphoid tissue. 
NOD.BDC mice transgenic for the diabetogenic BDC2.5 TCR were treated with either 
YTS177 or 2A3. YTS177 and 2A3-treated BDC CD4+ T cells were isolated from the spleen 
12 h later, differentially labeled with CTV, and then co-transferred at an equal ratio into 
NOD recipients. Included were splenic BDC CD4+ T cells isolated from NOD.BDC mice 
injected with αCD11α and αCD49d Ab, which block lymph node entry by T cells (52). As 
expected trafficking of αCD11α/αCD49d Ab-bound BDC CD4+ T cells into the PLN, but 
not the spleen, was significantly reduced (e.g. ~4-fold) relative 2A3-treated cells (Fig. 2). In 
contrast, the ratio of YTS177- versus 2A3-treated BDC CD4+ T cells was reduced only 
minimally in the PLN; whereas trafficking to the spleen was unaffected by YTS177 (Fig. 2). 
These results indicate that YTS177 binding has no significant effect on CD4+ T cell entry 
into the PLN.
Ab binding of CD4 enhances CD4+ T cell migration in vitro
The above results suggested that PLN purging by YTS177 binding was due to altered T cell 
migratory properties resulting in tissue egress. Migration of T cells from lymph nodes into 
blood (Fig. 1C) is controlled at least in part by circulating cues regulating tissue egress, such 
as S1P. Accordingly, CD4+ T cells were isolated from the PLN of NOD mice 24 h post-
treatment with YTS177 or 2A3, and chemotaxis towards S1P across a 5 μm transwell 
measured. The frequency of YTS177-bound PLN CD4+ T cells migrating in response to S1P 
was increased up to 3-fold compared to PLN CD4+ T cells from 2A3-treated NOD mice 
(Fig. 3A). Notably, YTS177 also enhanced PLN CD4+ T cell migration towards the CXCR4 
ligand CXCL12 up to 2-fold, relative to PLN CD4+ T cells from control NOD mice (Fig. 
3B).
PLN CD4+ T cells from YTS177-treated NOD mice also exhibited similar enhanced S1P 
migration under progressively more stringent barrier conditions. S1P-mediated chemotaxis 
of PLN CD4+ T cells from YTS177- versus 2A3-treated NOD mice was increased 2.5-fold 
in transwells coated with collagen (Fig. 3C). An analogous 2.5-fold increase in S1P 
migration was seen for YTS177-bound PLN CD4+ T cells when a monolayer of endothelial 
cells was cultured on the surface of the transwells (Fig. 3D). Importantly, under the 
conditions tested, chemotaxis of CD8+ T cells which were included was unaffected, 
demonstrating that enhanced migration was due to intrinsic effects of YTS177 binding to 
CD4 (Fig. 3C,D). Furthermore, in vivo YTS177 binding did not increase mRNA or surface 
protein expression of S1P1 receptor (r) and CXCR4 in PLN (or splenic) CD4+ T cells (Fig. 
3E,F). Taken together, these results indicate that YTS177 binding enhances CD4+ T cell 
migration in response to different chemotactic cues.
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Signaling downstream of CD4 engagement results in tissue-specific Rac activation
The small RhoGTPases Rac1 and Rac2 regulate actin cytoskeletal reorganization and 
migration of T cells. With this in mind, a role for Rac1 and/or Rac2 signaling downstream of 
CD4 engagement was investigated. NOD mice were treated with YTS177 or 2A3, T cells 
isolated from the PLN at various times, and activated Rac1 and Rac2 isolated from lysates 
via pull-down and analyzed by immunoblot. The level of active Rac1 and Rac2 was 
normalized to total levels for the two respective GTPases. YTS177 induced a temporal 
increase in both Rac1 and Rac2 activation relative to 2A3 controls in PLN T cells (Fig. 4A). 
Rac1 activation was detected by 1 h post-YTS177 treatment, and peaked by 6 h, resulting in 
an ~3-fold increase versus the 2A3 control (Fig. 4A). A similar temporal profile was seen for 
Rac2 activation in YTS177-bound PLN T cells; at 6 h, activation of Rac2 was ~8-fold 
greater relative to the 2A3 control (Fig. 4A). Notably, no increase in either Rac1 or Rac2 
activation was detected in splenic T cells isolated 6 h post-YTS177 treatment (Fig. 4B).
To determine if increased T cell migration (Fig. 3) was dependent on Rac activation, PLN T 
cells were transduced in vitro with lentiviral vectors encoding Rac1- and Rac2-specific 
shRNA, and migration in response to CXCL12 assessed. Protein expression of both Rac1 
and Rac2 was significantly knocked-down in T cells transduced with Rac1- and Rac2-
specific shRNA, respectively, and selected with puromycin (Supplementary Fig. 2B). As 
expected, non-transduced T cells, and T cells transduced with a control shRNA specific for 
β-globulin, displayed a significant increase in CXCL12 migration following YTS177 versus 
2A3 binding in vitro (Fig. 4C). In contrast, YTS177 failed to increase CXCL12 migration 
for T cells transduced with Rac1- or Rac2-specific shRNA alone, or with the respective 
shRNA combined (Fig. 4C).
Next an effort was made to identify the upstream GEF activating Rac1 and Rac2, and better 
define the signaling pathway induced by CD4 engagement. Initially, all activated RacGEF 
were isolated from PLN T cells by a Rac.G15A pulldown, and analyzed via immunoblot. No 
increase in activation of the known T cell RacGEF Vav1, Vav2, and Dock2 was detected in 
PLN T cells from YTS177 treated NOD mice (Fig. 5A). PI3K signaling in T cells is 
associated with activation of the RacGEF Vav1, Dock2, and Tiam1. YTS-mediated egress of 
PLN CD4+ T cells was unaffected by treating NOD mice with the PI3K inhibitor Ly294002 
(Fig. 5B), despite efficient PI3K inhibition marked by reduced steady state phosphorylation 
of AKT (Supplementary Fig. 2C). The latter finding is consistent with results obtained after 
active RacGEF pulldown (Fig. 5A). Taken together, these data provide evidence that the 
enhanced migratory phenotype induced by CD4 engagement is dependent on tissue-specific 
Rac1 and Rac2 activation, which in turn is regulated by a RacGEF independent of some the 
known T cell RacGEF.
DISCUSSION
A striking feature of the β cell-specific tolerance induced by coreceptor therapy is the 
purging of PLN and islet T cells in NOD mice. Our findings indicate that T cell purging is 
the result of modified trafficking properties established by αCD4 Ab binding that is 
dependent on activation of Rac1 and Rac2, leading to altered tissue retention and egress.
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The rate of T cell entry and egress contribute to the size of the resident T cell pool in 
lymphoid tissue. Therefore YTS177-induced purging of PLN CD4+ T cells may be due to 
blockade of T cell entry coupled with continued egress, and/or enhanced T cell egress. 
YTS177-bound BDC CD4+ T cells, however, entered and accumulated in the PLN similar to 
control treated T cells (Fig. 2). On the other hand, entry of transferred BDC CD4+ T cells 
bound by αCD11α and αCD49d into the PLN was markedly reduced (Fig. 2), consistent 
with the lymph node blockade induced by αCD11α and αCD49d shown by the Cyster 
group (52). These results suggest that CD4+ T cell entry into the PLN is not impacted, 
although minor perturbations cannot be ruled out. Efforts to determine if T cell egress is 
accelerated by YTS177 have been complicated by the rapid and robust nature of PLN T cell 
egress under “homeostasis” in NOD mice. For instance, complete blockade of T cell entry 
via αCD11α and αCD49d treatment, so that ongoing egress can be directly measured (52), 
resulted in >10-fold reduction in CD4+ (and CD8+) T cell numbers by 24 h in the PLN of 
NOD mice (Supplementary Fig. 3C). PLN purging by αCD11α and αCD49d was in fact 
more effective than YTS177, which reduced CD4+ T cells by ~2-fold after 24 h (Fig. 1B). 
This difference may be due to ongoing T cell entry (Fig. 2) that offsets, to a certain degree, T 
cell egress following YTS177 treatment. To better define the kinetics of egress following 
YTS177 treatment, comparisons were drawn between YTS177 plus αCD11α and αCD49d 
versus αCD11α and αCD49d-alone. However not surprisingly, in view of the robustness of 
CD11α and CD49d Ab-blockade, no marked difference was seen in PLN T cell purging 
among the respective groups (Supplementary Fig. 3D). A direct effect of YTS177 on PLN T 
cell egress still needs to be established. Nevertheless, our findings clearly demonstrate that 
YTS177 influences the dynamics of PLN T cell migration.
YTS177 treatment resulted in a variety of in vivo changes in PLN T cells which included a 
polarized morphology, downregulation of adhesion molecules, and enhanced reactivity to 
chemoattractants (Figs. 1,3). The increase in the frequency of polarized PLN T cells was 
explained by activation of Rac1 and Rac2 (Fig. 4), which are key regulators of cytoskeletal 
reorganization needed for T cell migration. Downregulation of LFA-1 would also be 
expected to enhance T cell egress from the PLN by reducing ICAM binding. For example, 
LFA-1 deficient T cells exhibit accelerated lymph node egress (53), and LFA-1 blockade 
promotes exit of naïve T cells from the lymph nodes into blood (54). Supporting these and 
our own observations is a report showing that LFA-1-mediated adhesion is decreased by in 
vitro αCD4 Ab binding to T cells (55). Chemotaxis assays provided direct evidence that 
YTS177 enhanced PLN T cell migration. Migration in response to S1P under increasingly 
stringent barrier conditions, as well as CXCL12 chemotaxis were elevated 2-3-fold by 
YTS177 binding in vivo (Fig. 3) and in vitro (Fig. 4C). Neither S1P1r nor CXCR4 
expression was increased (Fig. 3), suggesting that CD4 signaling enhances migration 
independent of modulating the level of CKR expression, which is consistent with enhanced 
clustering seen in polarized T cells. Whether the activity of other CKR is similarly affected 
by YTS177 needs to be determined. CD4 binding ligands such as HIV gp120 and IL-16 
have been reported to modulate CD4+ T cell migration (21, 22). However, in contrast to 
YTS177, CD4 binding by HIV-1 gp120 blocks S1P chemotaxis, whereas IL-16 desensitizes 
CXCR4 activity and blocks CXCL12 chemotaxis (56, 57). These findings suggest that 
distinct effects on T cell migration are established depending on the nature of CD4 
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engagement. Also whether CD4 binding occurs under homeostasis versus ongoing 
inflammation is also expected to determine how T cell migratory properties are influenced. 
Indeed, T cell purging by YTS177 in NOD mice was also detected in other lymph nodes, 
such as the brachial lymph nodes, which exhibit levels of IFNγ expression and in turn 
ongoing inflammation that are comparable to PLN (Supplementary Fig. 3A,B).
It is well established that TCR and CKR signaling induces Rac activation that leads to T cell 
polarization and migration. Our data demonstrate for the first time that CD4 signaling also 
activates the Rac pathway (Fig. 4). HIV-1 has been shown to activate Rac1 to facilitate 
membrane fusion events during infection, but this is attributed to binding of CCR5 and 
CXCR4, and not CD4 (21). Rac activation by PLN CD4+ T cells was an early event, 
detected within 1 h of YTS177 treatment (Fig. 4A). Noteworthy is that significant T cell 
purging was detected within 24 h post YTS177 injection (Fig. 1B), when high levels of Rac1 
and Rac2 activation were detected (Fig. 4A). Importantly, Rac1 and Rac2 activation was 
necessary for enhanced T cell migration; YTS177 failed to increase CXCL12 chemotaxis 
after knockdown of Rac1 and/or Rac2 protein expression (Fig. 4C). Interestingly, 
knockdown of Rac1 and/or Rac2 had no marked effect on the capacity of control 2A3-
treated T cells (e.g. untransduced, β-globulin transduced) to migrate in response to CXCL12 
(Fig. 4C). This may reflect activation of other RhoGTPases due to the in vitro preparation of 
the respective CD4+ T cell pools, which in turn enabled CXCL12 chemotaxis in a Rac1/2-
independent manner. Similarly, it is possible that additional RhoGTPases also regulate 
events induced following Ab binding of CD4. The novelty of CD4-mediated Rac activation 
was further highlighted in analyses of candidate RacGEF. Pulldown of all activated RacGEF 
and inhibition of relevant upstream signaling effectors showed that RacGEF known to be 
associated with TCR signaling and/or T cell migration (e.g. Vav1, Vav2, Dock2, Tiam1) 
were not activated following YTS177 binding (Fig. 5). This result argues for a scenario in 
which CD4 engages an “atypical T cell” RacGEF for Rac1 and Rac2 activation. Our data 
also suggest that activation of the Rac pathway is independent of CD4-mediated Lck 
signaling since YTS177 induced an increase in the inhibitory Lck isoform in vivo 
(Supplementary Fig. 2A).
Of particular interest was that activation of Rac1 and Rac2 correlated with ongoing 
inflammation. YTS177-induced Rac activation was detected in CD4+ T cells in the PLN but 
not the spleen (Fig. 4); the former being a site of established inflammation. We propose that 
prior T cell activation and/or local inflammatory mediators “pre-sensitize” resident T cells, 
and upon YTS177 binding to CD4, distinct signals (e.g. Rac activation) are elicited that 
influence migratory properties. Not all effects of YTS177 were inflammation-dependent; T 
cell expression of LFA-1 and CD62L for instance was reduced for both PLN and splenic 
CD4+ T cells (Fig. 1A, Supplementary Fig. 1B,C). Here, it is thought that these systemic 
effects combined with inflammatory induced “pre-sensitization” are needed to effectively 
alter T cell migration. Ongoing efforts indicate that coreceptor therapy suppresses 
proinflammatory cytokine production by islet and PLN resident T cells. Consequently, the 
local inflammatory milieu is dampened, including expression of various chemokines such as 
CXCL12, which function as retention cues (58). Lack of signals required for local retention 
coupled with altered migratory properties permit enhanced T cell egress. Of keen interest is 
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how inflammation “reprograms” T cell responsiveness to coreceptor signal transduction, 
leading to migration.
In summary, our data supports a model where Ab-mediated CD4 engagement of T cells 
found in an inflammatory milieu elicits signaling independent of the TCR, resulting in Rac1 
and Rac2 activation. Rac1 and Rac2 act as molecular switches regulating migration, and 
promoting T cell tissue egress in the absence of retention cues. The ability to control Rac 
activation and migration provides a unique approach to manipulate T cell-mediated 
autoimmunity and other pathological inflammatory responses.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. YTS177-induced T cell purging is associated with a polarized phenotype independent 
of TCR signaling
NOD mice were treated with YTS177 or 2A3, and CD3+ T cells analyzed. (A) 
Representative flow cytometric histograms and average MFI for CD4, CD62L, and CD11α 
expression by gated CD3+ T cells in the PLN 24 h post-2A3 (thin line) and YTS177 (heavy 
line) treatment. The αCD4 clone RM4-4 used for staining is not blocked by YTS177 (n=4; 
*p<0.05, Student’s t test). (B) Temporal analysis of the number of CD3+CD4+ T cells 
isolated from the spleen and PLN of YTS177 and 2A3-treated animals (n=5; *p<10−2, 
Student’s t test). (C) CD3+ T cell numbers per μl of blood in NOD mice following Ab 
treatment (day 0: prior to treatment; n=10; *p≤0.05, Student’s t test). (D) CD4+ T cell 
numbers in the spleen and PLN 5 d post-Ab treatment ± FK506 injected daily (n=6; 
*p≤0.05, Student’s t test). (E) Polarized splenic and PLN CD3+ T cells were enumerated 48 
h post-Ab treatment; at least 500 T cells were scored from each mouse (n=3-5) (*p≤0.05, 
Student’s t test). (F) Representative images of YTS177 treated/polarized and 2A3 treated/
nonpolarized T cells exhibiting localization of F-actin (green) and LFA-1 (red) (400X 
magnification with digital zoom). Data are representative of ≥ 3 experiments.
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Figure 2. YTS177-bound CD4+ T cells traffick into the PLN
Representative flow cytometric profiles of BDC CD4+ T cells from NOD mouse donors 
treated with YTS177, αCD11α/CD49d or 2A3, and transferred into NOD recipients. The 
ratio of YTS177 or αCD11α/CD49d- versus 2A3-treated BDC CD4+ T cells found in the 
spleen and PLN of recipients (n=3; *p≤0.005, αintegrin/2A3 versus YTS177/2A3 or 
2A3/2A3, Student’s t test) is provided. YTS177 and αCD11α/CD49d-treated BDC CD4+ T 
cells were labeled with a 10-fold increase of CTV (5 μM; right peak) relative to 2A3-treated 
cells (0.5 μM; left peak). Data are representative of 3 independent experiments.
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Figure 3. CD4+ T cells exhibit increased chemotaxis after YTS177 treatment
NOD mice were treated with 600 μg YTS177 or 2A3, and 24 h later PLN and splenic T cells 
isolated. Percent chemotaxis of CD4+ T cells to (A) S1P (n=3; *p<10−4, one way-ANOVA), 
and (B) CXCL12 (n=3; *p=0.01, one way-ANOVA). Percentage of input CD4+ (n=6) or 
CD8+ (n=4) T cells migrating across 5 μm (C) collagen and (D) endothelial cell coated 
transwells in response to 10 μM S1P (*p<0.05, Student’s t test). (E,F) Fold difference of 
S1P1r (E) and CXCR4 (F) RNA expression measured by qRT-PCR by isolated splenic and 
PLN CD4+ T cells from YTS177- versus 2A3-treated NOD mice (n=5). Representative flow 
cytometric histograms for (E) S1P1r and (F) CXCR4 staining of PLN CD3+CD4+ gated 
cells isolated 6 h post-YTS177 (bottom histogram) and 2A3 (middle histogram) treatment. 
Staining with isotype control Ab is depicted in the top histograms for each panel.
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Figure 4. Increased Rac1 and Rac2 activation in PLN but not splenic T cells after YTS177 
treatment
(A, B) T cells were isolated from NOD mice treated with YTS177 or 2A3, and activation of 
Rac GTPase examined by RBD-GST pulldown and immunoblot. (A) Representative blot 
showing Rac1 (upper) and Rac2 (lower) activation in isolated T cells. (B) Representative 
immunoblot of active Rac1 and Rac2 in T cells isolated from the spleen and PLN 6 h post-
treatment. (A, B) Representative blots of ≥2 independent experiments are shown. Right 
graphs show the means ± SEM of densitometry for immunoblots (*p≤0.05, Student’s t test). 
(C) Isolated CD4+ T cells were mock transduced (Untransduced) or transduced with 
lentiviral vectors encoding shRNA specific for Rac1, Rac2, or β-globulin (Control), and 
CXCL12 (100 ng/ml) chemotaxis measured (n=5). Data is representative of 2 independent 
experiments (*p≤0.05, Student’s t test).
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Figure 5. Rac activation in PLN T cells by YTS177 is independent of known T cell GEF
(A) Representative immunoblots of active GEF by GEF activation pulldown of T cells 
isolated 3 h post treatment from the PLN of NOD mice 3h following YTS177 or 2A3 
treatment. (B) CD4+ T cell numbers in the PLN 5 d post 2A3, YTS177, Ly294002-alone or 
YTS177+Ly294002 treatments (n=6; *p≤0.05, Student’s t test).
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